Your browser does not support JavaScript or it may be disabled!
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
Get Realtime News
on your webpage

About 824 results for "bristol myers squibb"

BMS, Celgene collaborate on a combination trial
Bio Spectrum Asia

BMS and Pfizer report positive results from Phase III AMPLIFY-...

Bristol-Myers Squibb (BMS) and Pfizer have reported results of a pre-specified secondary analysis of the Phase III AMPLIFY-EXT trial of Eliquis in patients with venous thromboembolism (VTE). The trial evaluated clinical and demographic predictors ... Pharmaceutical Business Review, 12 hours ago
BMS, Celgene collaborate on a combination trial Bio Spectrum Asia, 1 day ago

45 images for bristol myers squibb, 5 days ago
Jutia Group, 1 week ago
Jutia Group, 3 weeks ago
Irish Independent, 2 weeks ago, 1 month ago
Daily Caller, 1 month ago
Pharma Letter, 3 weeks ago
Bio, 5 days ago, 3 weeks ago, 1 month ago

Bristol Myers (BMY) Showing Bullish Technicals With Support At $49.58

A covered call identified by's patented algorithms on Bristol-Myers Squibb Co ("BMY) could yield about 3.18% (13.49% annualized, for comparison purposes only) in 86 days.
 Individual.com4 days ago Bristol Myers (BMY) Trading Near $50.39 Support Level  Individual.com5 days ago Bristol Myers (BMY) Showing Support Near $49.66  Individual.com1 week ago

Potential Bristol Myers (BMY) Trade Targets 3.73% Return

Bristol-Myers Squibb Co ("BMY) is a good candidate for a covered call at the $50.00 level. The Dec. '14 call at that price should fetch a credit of about $2.34, which means the entire position has a ...
 Individual.com3 days ago

Bristol-Myers' Oral HCV Treatment Daklinza Gets EU Clearance

Good news flowed in at Bristol-Myers Squibb Company ( BMY ) from Europe with the European Commission (:EC) approving the biopharmaceutical company's Daklinza as a combination therapy for treating adults infected with genotypes 1, 2, 3 and 4 of ...
 Yahoo! Finance4 days ago

Intercept Pharmaceuticals Inc. (ICPT), Bristol-Myers Squibb Co (BMY), Biogen Idec Inc (BIIB): Orbimed Advisors Top Stocks in Q2

Orbimed Advisors , led by Samuel Isaly , recently published its 13F filing with the U.S. Securities and Exchange Commission. For the second quarter of 2014, the hedge fund revealed 132 equity positions, worth $8.5 billion. Orbimed Advisors is a ...
 InsiderMonkey.com4 days ago

Bristol-Myers Hepatitis C Therapy Approved in EU

Bristol-Myers Squibb (NYSE: BMY ) won approval for its oral hepatitis C virus (HCV) drug Daklinza in the European Union Wednesday, as the company continued to carve out a niche in the increasingly competitive HCV space. The EU approved Daklinza ...
 Investor's Business Daily5 days ago

3 Reasons Bristol-Myers Squibb's Stock Could Rise

The patent cliff has forced most Big Pharmas to make major transformations in their businesses over the past few years. Bristol-Myers Squibb (NYSE: BMY Despite slumping sales for key drugs, Bristol-Myers had generated strong top-line growth ...
 Motley Fool1 week ago

Biocon unit extends partnership with Bristol-Myers Squibb

The two cos announced to renew their engagement, boosted by encouraging results in last 5 years, during when 6 drug molecules have been brought for further studies. BANGALORE: Biocon's subsidiary extended its partnership of drug discovery with US-based ...
 Economic Times2 months ago Biocon up 3.5%, Syngene extends tie up with US co for 5-yr  Money Control2 months ago Biocon gains on expanding tie-up with Bristol-Myers  Business Standard2 months ago Biocon gains after unit extends drug discovery partnership  Myiris2 months ago

Health Ministry’s new bid for cancer drug copy nixed

In what should come as relief for US drug major Bristol-Myers Squibb, the Ministry of Commerce has rejected a fresh proposal by the Health Ministry seeking a compulsory licence for production of a copy of its patented blood cancer drug, Dasatinib.
 Business Line2 months ago

Bristol-Myers Squibb Given Consensus Recommendation of Hold by Analysts (NYSE:BMY)

Shares of Bristol-Myers Squibb (NYSE:BMY) have earned a consensus rating of Hold from the eighteen analysts that are presently covering the stock, AnalystRatings.Net reports. One research analyst has rated the stock with a sell rating, eight have ...
 American Banking News22 hours ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts


Realtime News

on your Webpage

Add Widget >Get your members hooked!
Related Queries - bristol myers squibb
Get updated on latest news & your favorite topics right in your inbox!
More     Less